1-14 of 14
Alexa B. Schrock
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice

Debra L. Richardson, Julia C. F. Quintanilha, Natalie Danziger, Gerald Li, Ethan Sokol, Alexa B. Schrock, Ericka Ebot, Neeru Bhardwaj, Tanesha Norris, Anosheh Afghahi, Anthony Frachioni, Christina Washington, Lauren Dockery, Julia Elvin, Ryon P. Graf, Kathleen N. Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (20): 4644–4653.
https://doi.org/10.1158/1078-0432.CCR-24-1225
Published: 15 October 2024
View article titled, Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
Open the PDF for Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice in another window
Includes: Supplementary data
Journal Articles

RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Harshabad Singh, Pranshu Sahgal, Kevin Kapner, Steven M. Corsello, Hersh Gupta, Rahul Gujrathi, Yvonne Y. Li, Andrew D. Cherniack, Raquelle El Alam, Joseph Kerfoot, Elizabeth Andrews, Annette Lee, Chetan Nambiar, Alison M. Hannigan, Joshua Remland, Lauren Brais, Meghan E. Leahy, Douglas A. Rubinson, Benjamin L. Schlechter, Matthew Meyerson, Yanan Kuang, Cloud P. Paweletz, Jessica K. Lee, Julia C.F. Quintanilha, Andrew J. Aguirre, Kimberly J. Perez, Brandon M. Huffman, Humberto Rossi, Thomas A. Abrams, Sheheryar Kabraji, Livio Trusolino, Andrea Bertotti, Ewa T. Sicinska, Aparna R. Parikh, Brian M. Wolpin, Alexa B. Schrock, Marios Giannakis, Kimmie Ng, Jeffrey A. Meyerhardt, Jason L. Hornick, Nilay S. Sethi, James M. Cleary
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1669–1684.
https://doi.org/10.1158/1078-0432.CCR-23-2581
Published: 15 April 2024
View article titled, <em>RAS/RAF</em> Comutation and <em>ERBB2</em> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
Open the PDF for <em>RAS/RAF</em> Comutation and <em>ERBB2</em> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types

Pashtoon M. Kasi, Jessica K. Lee, Lincoln W. Pasquina, Brennan Decker, Pierre Vanden Borre, Dean C. Pavlick, Justin M. Allen, Christine Parachoniak, Julia C. F. Quintanilha, Ryon P. Graf, Alexa B. Schrock, Geoffrey R. Oxnard, Christine M. Lovly, Hanna Tukachinsky, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 836–848.
https://doi.org/10.1158/1078-0432.CCR-23-2693
Published: 16 February 2024
View article titled, Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Open the PDF for Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types in another window
Includes: Supplementary data
Journal Articles

Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study

Giovanni Randon, Yoshiaki Nakamura, Rona Yaeger, Sara Lonardi, Chiara Cremolini, Elena Elez, Federico Nichetti, Filippo Ghelardi, Vincenzo Nasca, Francesca Bergamo, Veronica Conca, Javier Ros, Hideaki Bando, Giulia Maddalena, Simone Oldani, Michele Prisciandaro, Alessandra Raimondi, Alexa B. Schrock, Luca Agnelli, Henry Walch, Takayuki Yoshino, Filippo Pietrantonio
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (2): 436–443.
https://doi.org/10.1158/1078-0432.CCR-23-1379
Published: 17 January 2024
View article titled, Negative Hyperselection of Patients with HER2<sup>+</sup> and <em>RAS</em> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Open the PDF for Negative Hyperselection of Patients with HER2<sup>+</sup> and <em>RAS</em> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study in another window
Includes: Supplementary data
Journal Articles

Unique Spectrum of Activating BRAF Alterations in Prostate Cancer

Alex Chehrazi-Raffle, Hanna Tukachinsky, Eamon Toye, Smruthy Sivakumar, Alexa B. Schrock, Hannah E. Bergom, Hedyeh Ebrahimi, Sumanta Pal, Tanya Dorff, Neeraj Agarwal, Brandon A. Mahal, Geoffrey R. Oxnard, Justin Hwang, Emmanuel S. Antonarakis
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (19): 3948–3957.
https://doi.org/10.1158/1078-0432.CCR-23-1393
Published: 02 October 2023
View article titled, Unique Spectrum of Activating <em>BRAF</em> Alterations in Prostate Cancer
Open the PDF for Unique Spectrum of Activating <em>BRAF</em> Alterations in Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma

Hope S. Rugo, Kira Raskina, Alexa B. Schrock, Russell W. Madison, Ryon P. Graf, Ethan S. Sokol, Smruthy Sivakumar, Jessica K. Lee, Virginia Fisher, Geoffrey R. Oxnard, Hanna Tukachinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1056–1067.
https://doi.org/10.1158/1078-0432.CCR-22-2115
Published: 14 March 2023
View article titled, Biology and Targetability of the Extended Spectrum of <em>PIK3CA</em> Mutations Detected in Breast Carcinoma
Open the PDF for Biology and Targetability of the Extended Spectrum of <em>PIK3CA</em> Mutations Detected in Breast Carcinoma in another window
Includes: Supplementary data
Journal Articles

SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer

Umang Swami, Ryon P. Graf, Roberto H. Nussenzveig, Virginia Fisher, Hanna Tukachinsky, Alexa B. Schrock, Gerald Li, Jeffrey S. Ross, Nicolas Sayegh, Nishita Tripathi, Vinay Mathew Thomas, Geoffrey R. Oxnard, Emmanuel S. Antonarakis, Neeraj Agarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4917–4925.
https://doi.org/10.1158/1078-0432.CCR-22-2228
Published: 14 November 2022
View article titled, SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in <em>De Novo</em> Metastatic Castration-Sensitive Prostate Cancer
Open the PDF for SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in <em>De Novo</em> Metastatic Castration-Sensitive Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA

Jessica K. Lee, Mehlika Hazar-Rethinam, Brennan Decker, Ole Gjoerup, Russell W. Madison, Daniel S. Lieber, Jon H. Chung, Alexa B. Schrock, James Creeden, Jeffrey Venstrom, Brian Alexander, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 728–737.
https://doi.org/10.1158/1078-0432.CCR-21-2136
Published: 15 February 2022
View article titled, The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Open the PDF for The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA in another window
Includes: Supplementary data
Journal Articles

Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas

Simona Corso, Filippo Pietrantonio, Maria Apicella, Cristina Migliore, Daniela Conticelli, Annalisa Petrelli, Laura D'Errico, Stefania Durando, Daniel Moya-Rull, Sara E. Bellomo, Stefano Ughetto, Maurizio Degiuli, Rossella Reddavid, Uberto Fumagalli, Stefano De Pascale, Giovanni Sgroi, Emanuele Rausa, Gian Luca Baiocchi, Sarah Molfino, Giovanni De Manzoni, Maria Bencivenga, Salvatore Siena, Andrea Sartore-Bianchi, Federica Morano, Salvatore Corallo, Michele Prisciandaro, Maria Di Bartolomeo, Annunziata Gloghini, Silvia Marsoni, Antonino Sottile, Anna Sapino, Caterina Marchiò, Asa Dahle-Smith, Zosia Miedzybrodzka, Jessica Lee, Siraj M. Ali, Jeffrey S. Ross, Brian M. Alexander, Vincent A. Miller, Russell Petty, Alexa B. Schrock, Silvia Giordano
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3126–3140.
https://doi.org/10.1158/1078-0432.CCR-20-0121
Published: 01 June 2021
View article titled, Optimized EGFR Blockade Strategies in <em>EGFR</em> Addicted Gastroesophageal Adenocarcinomas
Open the PDF for Optimized EGFR Blockade Strategies in <em>EGFR</em> Addicted Gastroesophageal Adenocarcinomas in another window
Includes: Supplementary data
Journal Articles

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw, Ryohei Katayama, Yuki Shimizu, Viola W. Zhu, Thomas Yang Sun, Heather A. Wakelee, Russell Madison, Alexa B. Schrock, Giorgio Senaldi, Naoki Nakao, Hiroyuki Hanzawa, Masaya Tachibana, Takeshi Isoyama, Kenji Nakamaru, Chenhui Deng, Meijing Li, Frank Fan, Qinying Zhao, Yanfei Gao, Takashi Seto, Pasi A. Jänne, Sai-Hong Ignatius Ou
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (18): 4785–4794.
https://doi.org/10.1158/1078-0432.CCR-20-1630
Published: 15 September 2020
View article titled, U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation

Benjamin P. Brown, Yun-Kai Zhang, David Westover, Yingjun Yan, Huan Qiao, Vincent Huang, Zhenfang Du, Jarrod A. Smith, Jeffrey S. Ross, Vincent A. Miller, Siraj Ali, Lyudmila Bazhenova, Alexa B. Schrock, Jens Meiler, Christine M. Lovly
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (11): 3341–3351.
https://doi.org/10.1158/1078-0432.CCR-18-3829
Published: 03 June 2019
View article titled, On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation
Open the PDF for On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation in another window
Includes: Multimedia, Supplementary data
Journal Articles

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

Alexa B. Schrock, Dean Pavlick, Samuel J. Klempner, Jon H. Chung, Brady Forcier, Allison Welsh, Lauren Young, Bryan Leyland-Jones, Rodolfo Bordoni, Richard D. Carvajal, Joseph Chao, Razelle Kurzrock, Jason K. Sicklick, Jeffrey S. Ross, Philip J. Stephens, Craig Devoe, Fadi Braiteh, Siraj M. Ali, Vincent A. Miller
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (8): 1881–1890.
https://doi.org/10.1158/1078-0432.CCR-17-3103
Published: 12 April 2018
View article titled, Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus
Open the PDF for Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus in another window
Includes: Supplementary data
Journal Articles

Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing

Alexa B. Schrock, Garrett M. Frampton, Dana Herndon, Joel R. Greenbowe, Kai Wang, Doron Lipson, Roman Yelensky, Zachary R. Chalmers, Juliann Chmielecki, Julia A. Elvin, Mira Wollner, Addie Dvir, Lior Soussan -Gutman, Rodolfo Bordoni, Nir Peled, Fadi Braiteh, Luis Raez, Rachel Erlich, Sai-Hong Ignatius Ou, Mohamed Mohamed, Jeffrey S. Ross, Philip J. Stephens, Siraj M. Ali, Vincent A. Miller
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (13): 3281–3285.
https://doi.org/10.1158/1078-0432.CCR-15-1668
Published: 30 June 2016
View article titled, Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing
Open the PDF for Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing in another window
Journal Articles

Abstract B15: The pan-BCR-ABL inhibitor ponatinib inhibits viability of gatekeeper mutant BCR-ABLT315I cells with greater potency than a nilotinib/MEK inhibitor combination

Alexa B. Schrock, Joseph M. Gozgit, Victor Rivera
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): B15.
https://doi.org/10.1158/1078-0432.MECHRES-B15
Published: 04 March 2013
View article titled, Abstract B15: The pan-BCR-ABL inhibitor ponatinib inhibits viability of gatekeeper mutant BCR-ABL<sup>T315I</sup> cells with greater potency than a nilotinib/MEK inhibitor combination
Open the PDF for Abstract B15: The pan-BCR-ABL inhibitor ponatinib inhibits viability of gatekeeper mutant BCR-ABL<sup>T315I</sup> cells with greater potency than a nilotinib/MEK inhibitor combination in another window